Literature DB >> 12745060

Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.

Zang Hee Lee1, Hong Hee Kim.   

Abstract

Receptor activator of nuclear factor kappa B (RANK) is a tumor necrosis factor receptor (TNFR) family protein that plays an important role in the regulation of bone and immune systems. Cellular responses to RANK ligand (RANKL) and the signal transduction pathways of RANK have been well characterized in osteoclasts and osteoclast precursor cells. RANKL induces the differentiation of osteoclast precursor cells and stimulates the resorption function and survival of mature osteoclasts. The RANK signaling mechanisms involved in these responses include the recruitment of TNF receptor-associated factor proteins, the activation of transcription factors (NF-kappaB, AP-1, and NFAT2), the cascades of mitogen-activated protein kinases (ERK, JNK, and p38), and the induction of Src- and phosphatidylinositol 3-kinase-dependent Akt activation. Despite the identification of several molecular targets, a comprehensive understanding of RANK signaling requires further studies on more complicated issues such as the temporal and spatial pattern of the engagement of signaling molecules and the precise relationship between the signaling pathway and the cellular response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745060     DOI: 10.1016/s0006-291x(03)00695-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  101 in total

1.  Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species.

Authors:  Ho Jin Moon; Sung Eun Kim; Young Pil Yun; Yu Shik Hwang; Jae Beum Bang; Jae Hong Park; Il Keun Kwon
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

2.  Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.

Authors:  Yuji Ito; Steven L Teitelbaum; Wei Zou; Yi Zheng; James F Johnson; Jean Chappel; F Patrick Ross; Haibo Zhao
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

3.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

4.  Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.

Authors:  Taesoo Kim; Kabsun Kim; Seoung Hoon Lee; Hong-Seob So; Junwon Lee; Nacksung Kim; Yongwon Choi
Journal:  J Biol Chem       Date:  2009-03-31       Impact factor: 5.157

5.  SLAT negatively regulates RANKL-induced osteoclast differentiation.

Authors:  Bang Ung Youn; Kabsun Kim; Jung Ha Kim; Jongwon Lee; Jang Bae Moon; Inyoung Kim; Yong-Wook Park; Nacksung Kim
Journal:  Mol Cells       Date:  2013-08-29       Impact factor: 5.034

6.  Akt Cys-310-targeted inhibition by hydroxylated benzene derivatives is tightly linked to their immunosuppressive effects.

Authors:  Ji Yeon Lee; Yong Gyu Lee; Jaehwi Lee; Keum-Jin Yang; Ae Ra Kim; Joo Young Kim; Moo-Ho Won; Jongsun Park; Byong Chul Yoo; Sanghee Kim; Won-Jea Cho; Jae Youl Cho
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

7.  MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption.

Authors:  Zhimin He; Jin He; Zhiqiang Liu; Jingda Xu; Sofia F Yi; Huan Liu; Jing Yang
Journal:  Biochimie       Date:  2014-07-24       Impact factor: 4.079

8.  Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis.

Authors:  J M Fakruddin; J Laurence
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

9.  p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.

Authors:  Jin He; Zhiqiang Liu; Yuhuan Zheng; Jianfei Qian; Haiyan Li; Yong Lu; Jingda Xu; Bangxing Hong; Mingjun Zhang; Pei Lin; Zhen Cai; Robert Z Orlowski; Larry W Kwak; Qing Yi; Jing Yang
Journal:  Cancer Res       Date:  2012-10-11       Impact factor: 12.701

10.  Mitogen- and stress-activated protein kinase 1 activates osteoclastogenesis in vitro and affects bone destruction in vivo.

Authors:  Jeongim Ha; Hyung Joon Kim; Hao Huang; Zang Hee Lee; Hong-Hee Kim
Journal:  J Mol Med (Berl)       Date:  2013-04-26       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.